{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:59:16Z","timestamp":1781528356134,"version":"3.54.1"},"reference-count":24,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Premedications used to prevent paclitaxel-associated infusion hypersensitivity reactions (iHSRs) can cause undesirable toxicities, such as sleep disturbance and weight gain. Although phase II data suggest that discontinuing premedications after paclitaxel-associated iHSRs may be safe and feasible in select patients without prior iHSRs, no prospective randomized trials have evaluated this approach.\n                    <jats:bold>Patients and Methods:<\/jats:bold>\n                    This randomized clinical trial enrolled patients with breast cancer receiving paclitaxel chemotherapy. Those who experienced no iHSRs with the first 2 doses of paclitaxel were randomized to either continue standard premedications (control arm) or to discontinue all premedications (investigational arm). Both arms were followed longitudinally for any subsequent iHSRs requiring parenteral rescue medications. Additionally, changes in weight, drug-related side effects, and quality of life were assessed.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 98 patients were randomized; 89 were evaluable (46 in the control arm and 43 in the investigational arm). Only 1 (2.3%) patient in the investigational arm experienced an iHSR, which resolved with rescue medications. No iHSRs occurred in the control arm. The estimated proportion of subjects who experienced a hypersensitivity reaction (exact binomial 95% CI) was 2.3% (95% CI, 0.1%\u201312.3%) in the investigational arm and 0.0% (95% CI, 0.0%\u20137.7%) in the control arm. Patients in the investigational arm reported significantly less sleep disruption (0.5 vs 1.7;\n                    <jats:italic>P<\/jats:italic>\n                    =.002) and unwanted appetite increases (1.0 vs 2.5;\n                    <jats:italic>P<\/jats:italic>\n                    =.0018).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Discontinuation of premedications after 2 uneventful paclitaxel doses was not associated with a high rate of subsequent iHSRs and resulted in fewer steroid-related side effects. This strategy may reduce unnecessary medication exposure, improve patient experience, and streamline clinical workflows. For patients who do not experience iHSRs during the first 2 paclitaxel treatments, discontinuing premedications appears safe and may improve tolerability.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7475","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:55:15Z","timestamp":1778262915000},"page":"251-256","source":"Crossref","is-referenced-by-count":0,"title":["Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial"],"prefix":"10.6004","volume":"24","author":[{"given":"Michael","family":"Berger","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Novotny","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Pariser","family":"Davenport","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Gatti-Mays","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Cody","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","unstructured":"Prescribing information for paclitaxel injection, for intravenous use. 2023. Accessed December 17, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216338s000lbl.pdf"},{"key":"B2","series-title":"Crit Rev Oncol Hematol","first-page":"103826","article-title":"Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper","volume":"180","author":"Faggiano A","year":"2022","unstructured":"Faggiano A, Mazzilli R, Natalicchio A,  Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2022;180:103826."},{"key":"B3","series-title":"Cancer","first-page":"2646","article-title":"An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy","volume":"122","author":"Dieli-Conwright CM","year":"2016","unstructured":"Dieli-Conwright CM, Wong L, Waliany S,  An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 2016;122:2646\u20132653."},{"key":"B4","series-title":"Cancer Nurs","first-page":"355","article-title":"The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer","volume":"37","author":"Guinan EM","year":"2014","unstructured":"Guinan EM, Connolly EM, Healy LA,  The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer. Cancer Nurs 2014;37:355\u2013362."},{"key":"B5","unstructured":"UpToDate Lexidrug. Diphenhydramine. Accessed October 29, 2024. Available at: https:\/\/online.lexi.com"},{"key":"B6","series-title":"Support Care Cancer","first-page":"1991","article-title":"Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction","volume":"20","author":"Berger MJ","year":"2012","unstructured":"Berger MJ, Dunlea LJ, Rettig AE,  Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2012;20:1991\u20131997."},{"key":"B7","series-title":"Support Care Cancer","first-page":"2019","article-title":"Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction","volume":"23","author":"Berger MJ","year":"2015","unstructured":"Berger MJ, Vargo C, Vincent M,  Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2015;23:2019\u20132024."},{"key":"B8","series-title":"Support Care Cancer","first-page":"2471","article-title":"Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing 2 previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy","volume":"26","author":"Parinyanitikul N","year":"2018","unstructured":"Parinyanitikul N, Tanpipattanakul W, Poovorawan N,  Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing 2 previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. Support Care Cancer 2018;26:2471\u20132477."},{"key":"B9","series-title":"Support Care Cancer","first-page":"927","article-title":"The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients","volume":"27","author":"de Castro Baccarin AL","year":"2019","unstructured":"de Castro Baccarin AL, Irene MN, de Iracema Gomes Cubero D,  The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. Support Care Cancer 2019;27:927\u2013931."},{"key":"B10","series-title":"Support Care Cancer","first-page":"495.","article-title":"Measuring symptoms and toxicities: a 35-year experience","volume":"31","author":"Loprinzi CL","year":"2023","unstructured":"Loprinzi CL, Novotny P, Ruddy KJ,  Measuring symptoms and toxicities: a 35-year experience. Support Care Cancer 2023;31:495."},{"key":"B11","series-title":"Med Care","first-page":"582","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman GR","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich WA. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582\u2013592."},{"key":"B12","series-title":"Oncologist","first-page":"927","article-title":"Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer","volume":"26","author":"Barroso-Sousa R","year":"2021","unstructured":"Barroso-Sousa R, Vaz-Luis I, Di Meglio A,  Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer. Oncologist 2021;26:927\u2013933."},{"key":"B1","unstructured":"Prescribing information for paclitaxel injection, for intravenous use. 2023. Accessed December 17, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216338s000lbl.pdf"},{"key":"B2","series-title":"Crit Rev Oncol Hematol","first-page":"103826","article-title":"Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper","volume":"180","author":"Faggiano A","year":"2022","unstructured":"Faggiano A, Mazzilli R, Natalicchio A,  Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2022;180:103826."},{"key":"B3","series-title":"Cancer","first-page":"2646","article-title":"An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy","volume":"122","author":"Dieli-Conwright CM","year":"2016","unstructured":"Dieli-Conwright CM, Wong L, Waliany S,  An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 2016;122:2646\u20132653."},{"key":"B4","series-title":"Cancer Nurs","first-page":"355","article-title":"The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer","volume":"37","author":"Guinan EM","year":"2014","unstructured":"Guinan EM, Connolly EM, Healy LA,  The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer. Cancer Nurs 2014;37:355\u2013362."},{"key":"B5","unstructured":"UpToDate Lexidrug. Diphenhydramine. Accessed October 29, 2024. Available at: https:\/\/online.lexi.com"},{"key":"B6","series-title":"Support Care Cancer","first-page":"1991","article-title":"Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction","volume":"20","author":"Berger MJ","year":"2012","unstructured":"Berger MJ, Dunlea LJ, Rettig AE,  Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2012;20:1991\u20131997."},{"key":"B7","series-title":"Support Care Cancer","first-page":"2019","article-title":"Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction","volume":"23","author":"Berger MJ","year":"2015","unstructured":"Berger MJ, Vargo C, Vincent M,  Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2015;23:2019\u20132024."},{"key":"B8","series-title":"Support Care Cancer","first-page":"2471","article-title":"Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing 2 previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy","volume":"26","author":"Parinyanitikul N","year":"2018","unstructured":"Parinyanitikul N, Tanpipattanakul W, Poovorawan N,  Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing 2 previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. Support Care Cancer 2018;26:2471\u20132477."},{"key":"B9","series-title":"Support Care Cancer","first-page":"927","article-title":"The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients","volume":"27","author":"de Castro Baccarin AL","year":"2019","unstructured":"de Castro Baccarin AL, Irene MN, de Iracema Gomes Cubero D,  The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. Support Care Cancer 2019;27:927\u2013931."},{"key":"B10","series-title":"Support Care Cancer","first-page":"495.","article-title":"Measuring symptoms and toxicities: a 35-year experience","volume":"31","author":"Loprinzi CL","year":"2023","unstructured":"Loprinzi CL, Novotny P, Ruddy KJ,  Measuring symptoms and toxicities: a 35-year experience. Support Care Cancer 2023;31:495."},{"key":"B11","series-title":"Med Care","first-page":"582","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman GR","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich WA. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582\u2013592."},{"key":"B12","series-title":"Oncologist","first-page":"927","article-title":"Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer","volume":"26","author":"Barroso-Sousa R","year":"2021","unstructured":"Barroso-Sousa R, Vaz-Luis I, Di Meglio A,  Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer. Oncologist 2021;26:927\u2013933."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-p251.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-p251.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-p251.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:47:59Z","timestamp":1781527679000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-p251.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7475","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}